NCT05341986

Brief Summary

Atrial fibrillation (AF) is the most common arrhythmia in the world, with significant morbidity and mortality. With appropriate oral anticoagulation, the risk of stroke due to atrial fibrillation decreases by 64%. Although atrial fibrillation is commonly diagnosed and treated in the Emergency Department (ED), oral anticoagulation is significantly underprescribed. Underprescribing has been attributed to a lack of empowerment and deferral of prescribing to longitudinal care clinicians. Using a convergent parallel quantitative-qualitative design (mixed-methods), we propose a stepped-wedge cluster randomized trial design with the implementation of a clinical decision support (CDS) tool in adults with new-onset AF that are OAC-naïve and at significant risk for stroke. In parallel, we will use qualitative approaches to evaluate clinician facilitators and barriers to tool utilization as well as patient satisfaction and engagement with the tool.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
36

participants targeted

Target at below P25 for not_applicable atrial-fibrillation

Timeline
Completed

Started Jan 2022

Typical duration for not_applicable atrial-fibrillation

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 11, 2022

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

April 13, 2022

Completed
9 days until next milestone

First Posted

Study publicly available on registry

April 22, 2022

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2026

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2026

Completed
Last Updated

March 20, 2025

Status Verified

March 1, 2025

Enrollment Period

4.1 years

First QC Date

April 13, 2022

Last Update Submit

March 17, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of patients appropriately prescribed OACs after CDS tool implementation.

    The primary outcome is the number of patients appropriately prescribed OACs after CDS tool implementation.

    through study completion, up to 4 years

Secondary Outcomes (1)

  • Clinician and patient feedback on acceptability and identification of barriers and facilitators to use of the tool.

    through study completion, up to 4 years

Study Arms (3)

Link-Out

OTHER

Clinicians will be trained on the web-based portal of the CDS tool and shown where the Link to the tool will be available in the EHR.

Other: Clinical Decision Support (CDS) tool

BPA + Link-out

OTHER

Clinicians will be trained on how a BPA is triggered when a patient is diagnosed with AF. The alert will pop up within the EHR with the Link-out to the web portal.

Other: Clinical Decision Support (CDS) tool

BPA + FHIR

OTHER

Instead of a link to the web-based portal, the BPA will contain a link to the FHIR-integrated CDS tool portal. FHIR will automatically pull EHR data about the patient into the CDS tool portal. Data include demographic information, comorbidities in the active problem list, past medical and surgical history, and social history. Clinicians will also receive training before the implementation of this step.

Other: Clinical Decision Support (CDS) tool

Interventions

Implementation of an EHR-based CDS tool for providers to use.

BPA + FHIRBPA + Link-outLink-Out

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • A diagnosis of atrial fibrillation or paroxysmal atrial fibrillation (ICD-10 I48.0, I48.1, I48.9) during an ED visit with start dates between 1/11/2022 and 12/31/2025 within the patient's age \>18 years.

You may not qualify if:

  • Valvular disease, pregnancy, large esophageal varices, thrombocytopenia, severe or uncontrolled bleeding, severe liver or kidney disease, major surgery within 72 hours; OR
  • Recent brain, eye or spinal cord injury or surgery; OR
  • ED stroke, death or hospitalization at index visit; OR
  • Patient transferred from another hospital (to ensure availability of index ED visit data); OR
  • Left against medical advice; OR
  • Evidence of non-OAC naïve patient:
  • OAC prescribed in the prior 3mo to index ED visit; OR
  • Being managed by an anticoagulation clinic (ACC);

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Oregon Health & Science University (OHSU)

Portland, Oregon, 97239, United States

Location

MeSH Terms

Conditions

Atrial Fibrillation

Interventions

Compact DisksEquipment and Supplies

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Videodisc RecordingOptical Storage DevicesAudiovisual AidsEducational TechnologyTechnologyTechnology, Industry, and AgricultureTelevision

Study Officials

  • Bory Kea, MD, MCR

    Oregon Health and Science University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: Using a convergent parallel quantitative-qualitative design (mixed-methods), we propose a stepped-wedge cluster randomized trial design with the implementation of an electronic health record (EHR) clinical decision support (CDS) tool in adults with new-onset AF that are OAC-naïve and at significant risk for stroke, in three ED settings with different practice patterns and culture, patient populations, and organizational readiness. In parallel, we will use qualitative approaches to evaluate clinician facilitators and barriers to tool utilization as well as patient satisfaction and engagement with the tool.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

April 13, 2022

First Posted

April 22, 2022

Study Start

January 11, 2022

Primary Completion

March 1, 2026

Study Completion

May 1, 2026

Last Updated

March 20, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations